Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635
| RARE Stock | USD 48.13 0.77 1.63% |
About 57% of Ultragenyx's investor base is looking to short. The analysis of the overall investor sentiment regarding Ultragenyx suggests that many traders are alarmed. The current market sentiment, together with Ultragenyx's historical and current headlines, can help investors time the market. In addition, many technical investors use Ultragenyx stock news signals to limit their universe of possible portfolio assets.
Ultragenyx |
NOVATO, Calif., Nov. 20, 2024 -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the companys common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the companys board of directors and granted under the Ultragenyx Emplo
Read at finance.yahoo.com
 |
Ultragenyx Current Investor Sentiment
Panic Vs Confidence
43
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ultragenyx's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ultragenyx.
News SentimentBearish | Hype SentimentNeutral | Insider SentimentDisposing |
Ultragenyx Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ultragenyx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ultragenyx Historical Investor Sentiment
Investor biases related to Ultragenyx's public news can be used to forecast risks associated with an investment in Ultragenyx. The trend in average sentiment can be used to explain how an investor holding Ultragenyx can time the market purely based on public headlines and social activities around Ultragenyx. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ultragenyx's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ultragenyx and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ultragenyx news discussions. The higher the estimate score, the more favorable the investor's outlook on Ultragenyx.
Ultragenyx Fundamental Analysis
We analyze Ultragenyx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultragenyx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultragenyx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Ultragenyx is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Ultragenyx Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ultragenyx stock to make a market-neutral strategy. Peer analysis of Ultragenyx could also be used in its relative valuation, which is a method of valuing Ultragenyx by comparing valuation metrics with similar companies.
Peers
Ultragenyx Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| TERN | Terns Pharmaceuticals | 7.82 | ||||
| ARVN | Arvinas | 6.13 | ||||
| AMLX | Amylyx Pharmaceuticals | 5.32 | ||||
| APLS | Apellis Pharmaceuticals | 4.63 | ||||
| KURA | Kura Oncology | 3.91 | ||||
| ABOS | Acumen Pharmaceuticals | 2.73 | ||||
| INZY | Inozyme Pharma | 2.64 | ||||
| PDSB | PDS Biotechnology | 1.90 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.59 | ||||
| DAWN | Day One | 1.33 | ||||
| INCY | Incyte | 0.87 | ||||
| UTHR | United Therapeutics | 0.30 | ||||
| ALNY | Alnylam Pharmaceuticals | 0.15 | ||||
| RVMD | Revolution Medicines | 0.09 |
Complementary Tools for Ultragenyx Stock analysis
When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |